TrialBlood advances2026

Safety, efficacy, and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B.

Benjamin J Samelson-Jones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.